Monday, May 19, 2008

Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study

Patients Transitioned from Alendronate to Denosumab Therapy Achieved Superior Gains in Bone Mineral Density Versus Those Continuing on Alendronate Therapy

THOUSAND OAKS, Calif. – May 19, 2008 – Amgen (NASDAQ: AMGN) today announced findings from a head-to-head, double-blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned from weekly alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone mineral density (BMD). The study demonstrated superior results for the primary and all secondary endpoints.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Thursday, May 15, 2008

Amgen Highlights Data to Be Presented at ASCO

New Data from Denosumab, Vectibix(R) and Mid-Stage Pipeline Demonstrate Progress of Oncology Portfolio

THOUSAND OAKS, Calif. – May 15, 2008 – Amgen (NASDAQ:AMGN) today announced it will present new data from the Company’s oncology portfolio on both approved and investigational cancer therapies at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting that will be held in Chicago from May 30 to June 3, 2008.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Tuesday, May 13, 2008

Amgen VP of Investor Relations Arvind Sood to Present at the Baird Growth Stock Conference

THOUSAND OAKS, Calif. – May 13, 2008 – Amgen (NASDAQ:AMGN) Vice President of Investor Relations Arvind Sood will present at the RW Baird Growth Stock Conference on Wednesday, May 14, 2008 beginning at 8:55 a.m. Central Time. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Wednesday, May 07, 2008

Amgen Announces Voting Results of Annual Meeting of Stockholders

THOUSAND OAKS, Calif. – May 7, 2008 – Amgen (NASDAQ:AMGN), today announced results of voting at the company’s Annual Meeting of Stockholders, held at the Four Seasons Hotel Westlake Village in Westlake Village, Calif. Approximately 86.9 percent of outstanding shares were represented at the meeting.

Read the rest of this entry

Posted in Press Releases

Tuesday, May 06, 2008

Amgen to Participate in CHMP Oncology Scientific Advisory Group Meeting in May

THOUSAND OAKS, Calif. – May 6, 2008 – Amgen (NASDAQ:AMGN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has requested Amgen and other erythropoiesis-stimulating agent (ESA) marketing authorization holders to participate in a closed meeting of the Scientific Advisory Group on Oncology (SAG-O) on May 15.

Read the rest of this entry

Posted in Press Releases